Multiple system atrophy and Parkinson’s disease are progressive nervous system disorders that affect everyday movements. Multiple system atrophy is rarer and tends to progress more quickly.

An experimental therapy for Parkinson's disease being developed by Roche and Prothena has missed the mark in a phase 2b trial ...

AC Immune SA has divulged compounds acting as α-synuclein (SNCA) aggregation inhibitors reported to be useful for the treatment of multiple system atrophy (MSA), Parkinson’s dementia, Lewy body ...

A new study published in the journal of Movement Disorders showed that Parkinson's disease (PD) was found to be independently ...

UCB’s Novartis-partnered investigational small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2a ...

After hours: December 20 at 6:12:06 PM EST Loading Chart for MSA ...

Nov. 12, 2024 — Researchers have identified a potential biomarker of Parkinson's disease progression. According to the new study, patients with a slow progression of ... Oct. 8, 2024 ...